checkAd
    Startseite > Aktien > Rezolute > Nachrichten
    Rezolute Aktie
    2,6600
     
    USD
    +2,31 %
    +0,0600 USD
    Letzter Kurs 27.04.24 Nasdaq
    2,6500
     
    USD
    6.600 STK
    Geldkurs 26.04.24
    2,6600
     
    USD
    200 STK
    Briefkurs 26.04.24
    ISIN: US76200L3096 · WKN: A2QEWP · SYM: RZLT · USA

    Neueste Nachrichten

    Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
    23.04.24 · globenewswire · Rezolute
    Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
    06.03.24 · globenewswire · Rezolute
    Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
    13.02.24 · globenewswire · Rezolute
    Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
    24.01.24 · globenewswire · Rezolute
    Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
    23.01.24 · globenewswire · Rezolute
    Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
    17.11.23 · globenewswire · Rezolute
    Rezolute Reports First Quarter Fiscal 2024 Results
    13.11.23 · globenewswire · Rezolute
    Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
    17.10.23 · globenewswire · Rezolute
    Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
    11.10.23 · globenewswire · Rezolute
    Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
    14.09.23 · globenewswire · Rezolute
    Rezolute to Participate in Upcoming Investor Conferences in September
    06.09.23 · globenewswire · Rezolute
    Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
    27.06.23 · globenewswire · Rezolute